Mridula George, MD, Talks Neoadjuvant TALA in gBRCA1/2 Mutation-Positive, Early HER2-Negative Breast Cancer
05/01/2021
Mridula George, MD, Rutgers Cancer Institute of New Jersey, discusses the results following the phase 2 study of neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer, presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.